RxDoctor Payments Data

Jeffrey Petersen, MD

Family Medicine · Fallbrook, CANPI 1699794735

Payments from drug & device makers

$1,369in general payments, 2019–2025

Across 76 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$290
  • AstraZeneca$260
  • AbbVie$118
  • Merck$88
  • Pfizer$87
  • Teva Pharmaceuticals USA, Inc.$66
  • plus $460 from 18 others

What the payments were for

  • Food & beverage$1,32997%
  • Education$403%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,369 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$144,891
Medicare patients
289
Services billed
2,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$127,101
XareltoRivaroxaban62$90,904
JanuviaSitagliptin Phosphate57$80,397
OzempicSemaglutide31$44,550
JardianceEmpagliflozin12$20,929
FarxigaDapagliflozin Propanediol18$16,024
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$14,418
MyrbetriqMirabegron17$11,669
SymbicortBudesonide/Formoterol Fumarate13$4,243
Levothyroxine Sodium362$3,783
Gabapentin187$3,716
VascepaIcosapent Ethyl11$3,649
LantusInsulin Glargine,hum.Rec.Anlog16$3,578
Atorvastatin Calcium363$3,143
SynthroidLevothyroxine Sodium44$2,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$87$127,101141 claims
MerckJanuvia$88$80,39757 claims
Novo NordiskOzempic$23$44,55031 claims
AstraZenecaFarxiga, Symbicort$260$20,26831 claims
GSKTrelegy Ellipta$290$14,41814 claims
Astellas Pharma US IncMyrbetriq$28$11,66917 claims
AbbVieSynthroid$118$2,89044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Fallbrook

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →